Use of a capillary blood collection device to monitor exposure to per- and polyfluoroalkyl substances (PFAS) in Veterans living in proximity to potential sources of environmental contamination
Havens et al.
The finding, in our words
Capillary whole blood collected and dried on the OneDraw device gave robust PFAS measurements with low limits of quantification, and levels of ten PFAS correlated strongly with matched venous plasma levels in 133 veterans, enabling remote sampling without clinical infrastructure.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
Guidance on capillary-to-plasma conversion: method- and analyte-specific clinical validation with paired capillary–venous samples before reporting plasma-equivalent results.
Boffel et al., Therapeutic Drug Monitoring (paywalled) · source ↗
Capillary dried blood spots, after haematocrit-dependent conversion, showed good agreement with plasma for 25-hydroxyvitamin D quantification, with 90 per cent of results within 20 per cent of plasma and substantial to almost perfect agreement in status classification, supporting reliable home self-collection for large-scale vitamin D monitoring.
Heughebaert et al., Clinical chemistry and laboratory medicine (paywalled) · source ↗
The study validated a semi-quantitative protocol for Epstein-Barr virus serology using dried blood spots, demonstrating 98.8% sensitivity and 96.5% specificity compared to paired venous serum samples. The successful validation in a self-sampling cohort confirms the suitability of this patient-centric microsampling approach for large-scale seroprevalence studies and decentralised trials.
This study validated a dried blood spot method for tacrolimus monitoring and demonstrated agreement with venous whole blood measurements in kidney transplant recipients. It also found that dried blood spot analysis of the biomarker CXCL-10 was elevated in patients experiencing rejection or infection, supporting its use for decentralised monitoring.